Literature DB >> 23358468

Mechanisms of resistance to EGFR targeted therapies.

Gorjan Hrustanovic1, Bianca J Lee, Trever G Bivona.   

Abstract

EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies are in widespread clinical use in patients with non-small cell lung cancer and other tumor types. Despite the clinical success of EGFR targeted therapy, resistance to treatment is a significant barrier to the optimized use of EGFR inhibitors to cure patients with lung and other cancers. Here, we review established and emerging mechanisms of resistance to EGFR targeted therapy and highlight strategies that could overcome treatment resistance and therefore enhance clinical outcomes.

Entities:  

Keywords:  EGFR; EGFR TKI; erlotinib; kinase; lung cancer; resistance; targeted therapy

Mesh：

Substances：

Year:  2013        PMID： 23358468      PMCID： PMC3667869          DOI： 10.4161/cbt.23627

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  133 in total

1.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Authors:  Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber
Journal:  Nat Genet       Date:  2005-10-30       Impact factor: 38.330

Review 2.  Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives.

Authors:  J P Spano; R Fagard; J-C Soria; O Rixe; D Khayat; G Milano
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

3.  Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

Authors:  Naheed Alam; Karen S Gustafson; Marc Ladanyi; Maureen F Zakowski; Atul Kapoor; Alexander M Truskinovsky; Arkadiusz Z Dudek
Journal:  Clin Lung Cancer       Date:  2010-09-01       Impact factor: 4.785

Review 4.  Inflammation meets cancer, with NF-κB as the matchmaker.

Authors:  Yinon Ben-Neriah; Michael Karin
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

5.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

6.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.

Authors:  James Bean; Gregory J Riely; Marissa Balak; Jenifer L Marks; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

9.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

10.  BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Authors:  Daniel B Costa; Balázs Halmos; Amit Kumar; Susan T Schumer; Mark S Huberman; Titus J Boggon; Daniel G Tenen; Susumu Kobayashi
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069
View more
  25 in total

Review 1.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.

Authors:  Arjan Gower; Yisong Wang; Giuseppe Giaccone
Journal:  J Mol Med (Berl)       Date:  2014-05-23       Impact factor: 4.599

2.  Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.

Authors:  Y Hasegawa; M Takahashi; S Ariki; D Asakawa; M Tajiri; Y Wada; Y Yamaguchi; C Nishitani; R Takamiya; A Saito; Y Uehara; J Hashimoto; Y Kurimura; H Takahashi; Y Kuroki
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

3.  A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens.

Authors:  Zhenzhen Zi; Yajie Zhang; Peng Zhang; Qing Ding; Michael Chu; Yiwen Chen; John D Minna; Yonghao Yu
Journal:  ACS Chem Biol       Date:  2020-01-03       Impact factor: 5.100

4.  Evaluation of the Mechanism of Jiedu Huazhuo Quyu Formula in Treating Wilson's Disease-Associated Liver Fibrosis by Network Pharmacology Analysis and Molecular Dynamics Simulation.

Authors:  Shao-Peng Huang; Sen Chen; Yan-Zhen Ma; An Zhou; Hui Jiang; Peng Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-06       Impact factor: 2.650

5.  Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.

Authors:  Wenlei Zhuo; Liang Zhang; Yi Zhu; Qichao Xie; Bo Zhu; Zhengtang Chen
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

6.  A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Authors:  Quincy S Chu; Randeep Sangha; Sebastien J Hotte; Gwen Sergenson; David Schnell; Vikram K Chand; Hal W Hirte
Journal:  Invest New Drugs       Date:  2014-07-19       Impact factor: 3.850

7.  Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.

Authors:  Junyoung Choi; Shinkyo Yoon; Deokhoon Kim; Yong Wha Moon; Chang Hoon Lee; Seyoung Seo; Jaekyung Cheon; Yong Song Gho; Changhoon Kim; Eung Ryoung Lee; Soo-Youl Kim; Kyoungmin Lee; Joo Young Ha; Sook Ryun Park; Sang-We Kim; Kang-Seo Park; Dae Ho Lee
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

8.  Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).

Authors:  Shao Ma; Ning Yin; Xiaomei Qi; Sandra L Pfister; Mei-Jie Zhang; Rong Ma; Guan Chen
Journal:  Oncotarget       Date:  2015-05-30

Review 9.  mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.

Authors:  M Janaki Ramaiah; K Rohil Kumar
Journal:  Mol Biol Rep       Date:  2021-06-16       Impact factor: 2.316

10.  The epidermal growth factor receptor (EGFR / HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer.

Authors:  Vahid Bemanian; Torill Sauer; Joel Touma; Bjørn Arne Lindstedt; Ying Chen; Hilde Presterud Ødegård; Katja Marjaana Vetvik; Ida Rashida Bukholm; Jürgen Geisler
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.